💸 The Tape

Three months after Curaleaf went hostile, Aurora Cannabis has an answer: a friendly, board-approved, fully financed merger with Organigram Global that values Aurora at C$7.80 per share, or roughly C$561 million on a fully diluted basis. That’s a 93% premium to Aurora’s unaffected price on August 10 and, more to the point, a 21% premium to the current implied value of Curaleaf’s bid. Curaleaf’s response on Tuesday was a statement that acknowledges the deal, questions its terms, calls Aurora “a significantly smaller, underperforming and less liquid company,” and says its own bid “remains outstanding.” It did not say the word “raise.”

What Organigram is offering

The structure is the tell. Aurora shareholders can choose C$7.80 in cash, 5.8626 Organigram shares, or C$3.75 cash plus 3.0431 shares, with proration against caps of C$253.6 million in cash and 205.8 million Organigram shares. That optionality is designed to beat Curaleaf on exactly the ground where Curaleaf is weakest. Curaleaf’s offer is 0.4013 of its own shares plus US$1.00 cash, capped at US$5.00. With CURA stock having slipped since October, that package is worth roughly US$4.60 today, or around C$6.45. Organigram is offering C$7.80 with a real cash election, and for Canadian holders who take stock, a tax-deferred rollover that Curaleaf’s U.S.-listed paper can’t provide.

The financing is already in place. BAT is buying 141 million Organigram shares at C$1.33 for about C$187.5 million, and ATB has underwritten up to C$210 million in credit facilities, including a C$115 million term tranche earmarked for the acquisition. Both boards approved unanimously. Aurora’s special committee recommended it. Fairness opinions came from BMO on the Organigram side and Fort Capital and Origin Merchant on Aurora’s. BAT signed an irrevocable voting agreement that survives six months past any termination, and directors and officers of both companies are locked up. Aurora’s board is now formally telling shareholders to reject Curaleaf, withdraw tendered shares and vote for Organigram.

The combined company would be the largest Canadian LP by a wide margin, with more than C$50 million in identified run-rate synergies, Aurora’s EU-GMP footprint in Germany and Australia bolted onto Organigram’s domestic scale and BAT’s balance sheet. Aurora holders end up with about 35% of the economics and 42% of the vote. Special meetings are targeted for December, closing for January 2027, subject to German FDI clearance and B.C. court approval.

Curaleaf’s position

Curaleaf’s statement is a holding action. It says the Organigram announcement omits a break fee, post-closing governance and BAT’s investor rights, which is fair; the press release doesn’t disclose them, and the arrangement agreement will. It argues its own bid offers “a stronger capital markets profile, greater certainty and speed to close, and greater anticipated synergies,” without quantifying any of those. It takes a shot at BAT’s “disappointing cannabis investment track record,” which is accurate and also irrelevant to whether BAT’s C$187.5 million clears. And it accuses Aurora’s board of “gross dereliction of their fiduciary duties” for refusing to engage, a line that only makes sense if Curaleaf was prepared to pay more than it has offered.

That’s the question.

Can Curaleaf go higher?

Mechanically, yes. A hostile bidder can amend its offer at any time before expiry, and Curaleaf’s expires December 4, before Aurora’s shareholder vote. Nothing in Canadian takeover law prevents it. The constraint is capacity, not permission.

The bigger problem is that Curaleaf would be bidding against a package Aurora’s board has already endorsed, with synergies Aurora’s advisors have already blessed and a strategic partner, BAT, that has a lock-up. A revised hostile bid would have to be high enough that Aurora’s board couldn’t credibly maintain its recommendation without breaching its own fiduciary duty, which means not just matching but clearing C$7.80 by a visible margin, probably C$8.25 or higher. At that price, Curaleaf is paying roughly 14x Aurora’s forward EBITDA for a company whose own management guides to declining revenue, in a transaction Curaleaf’s lenders will have to approve.

What Curaleaf can do instead

There are three other plays, none of them great. It can vote against the arrangement by buying Aurora shares in the market before the December record date and campaigning for a no vote; the deal needs two-thirds of votes cast plus a majority-of-the-minority, so a determined 20% block could sink it. It can challenge the lock-ups and deal protections in court if the arrangement agreement contains a break fee or no-shop that looks preclusive, though Canadian courts rarely intervene on those grounds. Or it can walk, let the bid expire December 4, book the exercise as having forced Aurora into a sale and move on to the Florida and European priorities it has been talking about all year.

Watch for the arrangement agreement on SEDAR+. The break fee size, the matching rights and BAT’s governance terms will tell you how much room Curaleaf has. A break fee under 3% and a standard right-to-match clause means the door is open. A fee at 4% plus BAT board seats means Aurora built this deal to be unbreakable.

The read

Curaleaf wanted Aurora’s Leuna facility, its German market share and its cash at a discount, and it bet that Aurora’s board had no alternative. It was wrong. Organigram showed up with BAT’s money, a cash election and a premium, and the board took it. Curaleaf can raise, but every dollar it adds now goes to the shareholders of a company it called underperforming, to top a deal it called inferior, using stock it says is undervalued. That’s a hard story to tell your own investors. The smarter move may be to make Aurora’s shareholders prove they prefer C$7.80 in a December vote, and let the market decide whether Curaleaf’s walkaway was the best trade it made all year.

📈 Dog Walkers

Amendment 8 Got MASSacred

Question 8 didn’t lose. It got buried. With early returns showing the repeal measure trailing 72% to 28%, Massachusetts voters delivered the most lopsided verdict on cannabis policy since the state legalized in 2016, and the first time any state’s adult-use market has been put to a repeal vote and survived.

The result matters beyond the Commonwealth. The Yes campaign was bankrolled almost entirely by SAM Action, the Virginia-based fundraising arm of Smart Approaches to Marijuana, which poured more than $3 million into a measure that needed misleading signature gatherers to reach the ballot and a confusing Yes-means-repeal structure to have any chance on it. SAM ran the same play in Maine on the same night. Massachusetts was the test case for whether a national prohibition group could buy back a mature legal market, and the answer was a 44-point no.

The coalition that beat it was unusually broad. Governor Healey and her Republican challenger Mike Minogue both opposed repeal. Warren, Markey and Pressley lined up against it, as did more than 50 legislators including the House Speaker and Senate President, the SEIU, the Marijuana Policy Project and more than 50 current and former law enforcement officers. The Cannabis Control Commission, which takes no formal position, nonetheless warned that repeal “could eliminate thousands of jobs, hundreds of businesses and billions in tax revenue.” On a $10 billion cumulative market generating $1.6 billion a year, that wasn’t hyperbole.

For operators, the immediate relief is that Curaleaf, Green Thumb, Verano, Ascend and the state’s independents keep their Massachusetts licenses and the capital behind them. The longer-term signal is to SAM’s donors. MPP had warned that even a close loss would “spook markets” and invite copycat repeals. A 72-28 blowout does the opposite. It tells every other adult-use state that voters who’ve lived with legal cannabis for eight years aren’t interested in going back, and it makes the next repeal campaign a much harder fundraising pitch.

📺 Trade To Black

Why Organigram Topped Curaleaf's Hostile Bid for Aurora | TTB Presented by Flowhub

• Organigram agrees to buy Aurora for C$7.80 a share, a C$561M deal at a 93% premium to Aurora’s pre-Curaleaf price and 21% above the hostile bid. BAT is backing it with C$187.5M, both boards approved, and the companies see C$50M+ in synergies.

• Pristine Capital’s Andrew O’Connell reviews the week’s price action as momentum builds across cannabis equities and the ALJ stay expires Thursday, with his read on what follows.

• ATACH’s Michael Bronstein breaks down the DEA’s weekend move registering 900+ medical dispensaries in seven states, and the orders to show cause sent to dual-licensed operators in California, D.C., Illinois and Minnesota.

• Bronstein also weighs in on what a Democratic sweep of the House and Senate in today’s midterms would mean for cannabis and hemp policy heading into 2027.